Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650451 | 0.84 | PARP1 (0.44) | PARP1GPR119NAMPT | |
| SCHEMBL7406307 | 0.78 | GABRP (0.45) | GSK3BDYRK1ALCK | |
| SCHEMBL19968019 | 0.75 | HSP90AA1 (0.40) | TRPV4SPR | |
| SCHEMBL28085713 | 0.73 | ALDH1A1 (0.48) | POLB | |
| SCHEMBL6469040 | 0.73 | LCK (0.46) | GSK3BDYRK1ALCKSCN9A | |
| SCHEMBL21584977 | 0.72 | LCK (0.42) | GSK3BDYRK1ALCKSCN9A | |
| SCHEMBL24819762 | 0.71 | LCK (0.41) | GSK3BDYRK1ALCKSCN9A | |
| SCHEMBL7110406 | 0.71 | LCK (0.48) | GSK3BDYRK1ALCK | |
| SCHEMBL6469038 | 0.71 | LCK (0.41) | GSK3BDYRK1ALCKSCN9A | |
| SCHEMBL30050964 | 0.71 | LCK (0.41) | GSK3BDYRK1ALCKSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | GSK3B 339/4885DYRK1A 691/4885PARP1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.